Aller au contenu principal
Profil bibliographique

Lokman Koral

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

118Publications signalées
345Citations signalées
3Affiliations récentes

Les institutions déclarées

Les domaines associés

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchBreast Lesions and CarcinomasNausea and vomiting managementLung Cancer Diagnosis and Treatment

Les publications récentes

Accès ouvert 2026 article OpenAlex

Onkoloji servisinde takip edilen geriatrik hastaların yatış sürelerinin ve klinik bulgularının değerlendirilmesi

Burak Tok, Lokman Koral

Amaç: Hastanemiz Tıbbi Onkoloji Servisi’ne yatan 65 yaş ve üzeri hastaların klinik özellikleri hakkın-da bilgi edinmeyi hedefliyoruz. Ayrıca, giderek yaşlanan nüfus göz önünde bulundurularak, ileriye dö-nük bakım koşullarının iyileştirilmesine, bakım merkezleri ile sağlık personeli sayısının planlanmasına katkı sağlamayı amaçlıyoruz.Yöntem: Tıbbi Onkoloji Servisi’ne …

tr (code pays fourni par la source)

0 citations Troia Medical Journal
Accès ouvert 2026 article OpenAlex

Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors

Mustafa Gürbüz, Deniz Tural, Timuçin Çil, Hacer Demir et autres

PURPOSE: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are clinically significant in patients with cancer, as chemotherapy can trigger viral reactivation, leading to liver failure, treatment interruption, or death. Despite this risk, routine viral screening in patients with solid …

tr (code pays fourni par la source)

0 citations JCO Global Oncology
Accès ouvert 2025 conference-abstract OpenAlex

The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

Nedim Turan, Timuçin Çil, Mehmet Artaç, İlhan Hacıbekiroğlu et autres

e20501 Background: The role of biomarkers in the treatment of non-small cell lung cancer is increasing. Biomarker evaluation is performed in almost all of the diagnosed patients and treatments are applied according to this evaluation. In this study, the frequency and testing …

tr (code pays fourni par la source)

0 citations Journal of Clinical Oncology
Accès ouvert 2025 article OpenAlex

Difficulty in emotion regulation, psychological resilience, and depression are associated with Prolonged Grief Disorder in patients with breast cancer

Barantsevich Er, Şükrü Alperen Korkmaz, Lokman Koral, Demet Güleç Öyekçin

Objective: Grief is a natural reaction to potential losses faced by women with breast cancer.To our knowledge, no study has been conducted on prolonged grief disorder (PGD) in women with breast cancer.This study investigated the sociodemographic, cancer-specific, and psychological factors affecting PGD …

us, tr (code pays fourni par la source)

1 citation Journal of Clinical Psychiatry
Accès ouvert 2024 article OpenAlex

Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study

Mustafa Değirmenci, Gülden Dınız, Dudu Solakoğlu Kahraman, Mustafa Şahbazlar et autres

Background: Trastuzumab is commonly utilized in the management of metastatic HER2-positive breast cancer. Our main goal was to examine the clinical outcomes and immune markers of patients who received trastuzumab and chemotherapy treatment. Methods: Between 1995 and 2012, a total of 98 …

tr (code pays fourni par la source)

1 citation Breast Cancer Targets and Therapy
Accès ouvert 2024 article OpenAlex

Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy

Murat Araz, İsmail Beypınar, Fatih İnci, Lokman Koral et autres

IntroductionWe compared the efficacy of first-generation granisetron and second-generation palonosetron in triplet anti-emetic prophylaxis in patients with non-small cell lung cancer (NSCLC) receiving cisplatin-based high emetogenic chemotherapy (HEC).MethodsThis prospective, multicenter, non-randomized, observational study was conducted between June 2018 and December 2021. Patients …

tr (code pays fourni par la source)

0 citations Journal of Oncology Pharmacy Practice
Accès ouvert 2024 conference-abstract OpenAlex

Are the results of clinical trials in patients with NSCLC reflected in real life? The Registurk-Lung study.

Mehmet Artaç, Mahmut Emre Yıldırım, Ahmet Taner Sümbül, Akın Öztürk et autres

e20512 Background: Evaluation of real-world data together with data in clinical studies is very important in the evaluation of treatment algorithms. In real life, treatments are applied to the elderly, patients with poor performance and unusual groups with comorbidities. Determining these treatment …

tr (code pays fourni par la source)

0 citations Journal of Clinical Oncology
Accès ouvert 2024 preprint OpenAlex

Investigating The Correlation Between Prolonged Survival In Patients With Advanced HER2+ Breast Cancer And The Activity Of Regulatory T Cells.

Mustafa Değirmenci, Gülden Dınız, Dudu Solakoğlu Kahraman, Mustafa Şahbazlar et autres

Abstract Purpose Trastuzumab is commonly utilized in the management of metastatic breast cancer. Our main goal was to examine the extended outcomes of patients experiencing a persistent positive response to trastuzumab treatment. Methods Between 1995 and 2012, a total of 98 patients …

tr, kh, Somalie (code pays fourni par la source)

0 citations Research Square
Accès ouvert 2024 article OpenAlex

46P The frequency of driver mutations in non-small cell cancer patients: Analysis of the 5064 patients in the Turkish nation-wide, observational, registurkLung study

Murat Yıldırım, Timuçin Çil, Mehmet Artaç, İlhan Hacıbekiroğlu et autres

The role of driver mutations and PDL-1 status in the treatment of NSCLC is increasing. Biomarker evaluation is performed in almost all of the patients and treatments are applied according to this evaluation. In this study, the frequency and testing rates of …

tr (code pays fourni par la source)

0 citations ESMO Open
Accès ouvert 2022 article OpenAlex

Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib

Yakup İriağaç, Eyyüp Çavdar, Kubilay Karaboyun, Seher Yıldız Tacar et autres

ABSTRACT Introduction: Crizotinib is a tyrosine kinase inhibitor used in patients with non-small cell lung cancer, and there are uncertainties about its effect on kidney function. In this study, it was aimed to document the possible adverse effect of the drug on …

tr (code pays fourni par la source)

3 citations Journal of Cancer Research and Therapeutics

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.